BMS-986368: Clinical Trials

2 trials of BMS-986368, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Recruiting 2

Follow BMS-986368: new trials by email Literature Review of BMS-986368 trials Research Report on BMS-986368

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368, Placebo - Agitation, Alzheimer Disease
Phase 2RecruitingCelgene1202025-06-092026-10-06
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
BMS-986368, Placebo - Multiple Sclerosis Spasticity
Phase 2RecruitingCelgene2002025-06-052026-10-27

Conditions studied

Alzheimer Disease (1)  ·  Multiple Sclerosis (1)  ·  Muscle Spasticity (1)  ·  Psychomotor Agitation (1)

Sponsors

Celgene (2)

Countries

Australia (2)  ·  United States (2)  ·  Argentina (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Germany (1)  ·  Poland (1)  ·  Puerto Rico (1)